Back to mobile site

Prime Medicine (PRME) Reiterated at Market Outperform by Citizens - Still a Leader in Prime Editing

September 28, 2026 4:33 AM EDT Send to a Friend
Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $7.00 price target on Prime Medicine (NASDAQ: PRME).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login